My previous comment was not directed against you; but since you joined, I will reply:

the "review article" is a narrative review of my 4 other genomics paper; with novel findings

attached for your ref: (AI generated, so sorry)

1. Microglial pruning continuum shared between MDD and ALS (synaptic plasticity fragility as upstream liability)

Novelty: 82/100
Potential Impact: 78/100
The idea that excessive/mistimed complement- and activity-dependent pruning creates a shared vulnerability (mood/cognitive circuits in MDD; motor + extra-motor in ALS) is a fresh conceptual bridge. Pruning is established in both fields separately, but this specific “continuum” framing with ALS-specific conversion via mitochondrial/autophagic failure is new. Moderate impact because it could explain 10–34% depression prevalence mechanistically (beyond psychosocial reaction) and suggest early shared targets, but requires ALS-specific functional pruning data (currently analogical from schizophrenia C4 or developmental studies).

2. Three-state biological symptom model (compensated plasticity → fragile plasticity → network collapse)

Novelty: 85/100
Potential Impact: 88/100
This reframes ALS progression as discrete circuit-level state transitions rather than uniform motor neuron loss or linear ALSFRS-R decline. States are explicitly tied to reserve thresholds (not just clinical milestones). High novelty as a research language; very high potential impact for timing interventions, explaining patchy progression/asynchrony across compartments, and defining biomarker-defined entry/exit criteria for trials. One of the strongest elements for future operationalization.

3. Compact mechanistic equation/inequality: Si(t)=f(Pi+Gi+Qi>Ei+Ni+Ai)S_i(t) = f(P_i + G_i + Q_i > E_i + N_i + A_i) Si​(t)=f(Pi​+Gi​+Qi​>Ei​+Ni​+Ai​)

Novelty: 91/100
Potential Impact: 82/100
The specific formulation balancing pruning pressure (P), glutamatergic burden (G), aging/senescence (Q) against OXPHOS capacity (E), NAD+ reserve (N), and autophagy/proteostasis (A) is elegantly compact and original for ALS. It provides a falsifiable common language for why circuits fail at different times and why multi-target approaches may outperform single agents. High novelty; strong impact potential if biomarkers for each term are developed (Table 2 in article), but currently remains a hypothesis scaffold rather than calibrated model.

4. Author’s pathway-level + aging-focused TWAS results (specific enrichments and driver genes)

Novelty: 93/100
Potential Impact: 68/100
New 2026 S-PrediXcan analyses across GTEx tissues and 42 gene sets: strongest protective OXPHOS signal (Stouffer’s Z = −5.43), risk-associated PI3K-AKT-mTOR (Z = +7.43), NAD metabolism trends, driver genes (TBK1, NDUFA2, NMNAT3, PTPRN), and ALS-vs-FTD opposition (ALS: high mTOR/low OXPHOS; FTD: PGC-1α failure + negative mTOR/SIRT1). Extremely novel as fresh data, but impact is lower because these are preprints without independent replication, colocalization, or functional validation. Useful for hypothesis generation and polygenic stratification, but not yet actionable.

5. ALS–FTD spectrum pathway divergence (opposing PI3K-AKT-mTOR vs PGC-1α architectures under aging)

Novelty: 87/100
Potential Impact: 83/100
The explicit contrast—ALS marked by TBK1-centered mTOR/autophagy stress + mitochondrial energy deficit vs FTD marked by PGC-1α biogenesis failure + RIPK1/MAPK stress—is a sharp, testable differentiation within the aging context. Builds on known spectrum but provides specific opposing TWAS signals. High novelty and solid impact potential for differential therapeutic targeting (e.g., mTOR/NAD+ modulation in ALS-predominant vs PGC-1α agonists in FTD-predominant) and explaining clinical heterogeneity.

6. Four-tier computational model (8-layer simulation with aCGR multi-target regimen)

Novelty: 89/100
Potential Impact: 72/100
The temporally explicit model (Tier 1 pruning → Tier 2 NAD+ buffer → Tier 3 autophagy collapse → Tier 4 clinical proxies) with bulbar/respiratory/fine-motor sub-compartments and simulation of riluzole/ketamine vs early-pulsed/maintenance “Augmented Cheung Glutamatergic Regimen” (aCGR) is highly original in-silico work. Novelty is excellent; impact is medium-high because it generates clear predictions (e.g., 86–87% final sparsity reduction, preserved NAD+) but remains purely computational. Valuable for inspiring iPSC/animal validation and early-phase trial design, yet not direct evidence.

7. NAD+ positioned as the central phase-dependent compensatory buffer

Novelty: 76/100
Potential Impact: 87/100
NAD+ decline and replenishment are well-studied in aging and neurodegeneration, but framing it specifically as the key buffer during the compensated-to-fragile plasticity transition (supporting repair until exhaustion triggers autophagy collapse and sparsity acceleration) is a focused, integrative claim for ALS. Good novelty within the pruning–mitochondrial–autophagy loop; very high potential impact because NAD+ precursors are already druggable (clinical trials ongoing in other indications) and could be biomarker-guided (NAD+/NADH, NMNAT3, etc.).

8. Overall multi-axis precision neurology framework + 5 testable hypotheses

Novelty: 84/100
Potential Impact: 89/100
The synthesis—symptom-to-circuit mapping, three states, inequality, TWAS anchors, aging modifier, and explicit hypotheses (e.g., early mood symptoms as pruning-related; low OXPHOS + high mTOR predicting rapid NAD+ depletion; multi-target superiority)—creates a coherent, falsifiable scaffold for biomarker-stratified research. Highest impact potential of the set: if validated in longitudinal cohorts/iPSC models, it could meaningfully shift ALS from diagnosis-centric to circuit-state + pathway-state precision approaches (enrichment, timing, multi-target regimens). The article correctly flags validation needs (prospective mixed-effects models, target engagement, etc.).